EC
AGIO icon

EntryPoint Capital’s Agios Pharmaceuticals AGIO Stock Holding History

EntryPoint Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,804
Closed -$256K – 659
2024
Q4 		$256K Buy
+7,804
New +$367K 0.11% 465
2024
Q2 		– Sell
-2,924
Closed -$85.5K – 1369
2024
Q1 		$85.5K Sell
2,924
-537
-16% -$14.4K 0.08% 507
2023
Q4 		$77.1K Buy
+3,461
New +$77.6K 0.07% 511

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

EntryPoint Capital's AGIO Position: Q1 2025 in Review

EntryPoint Capital sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 7,804 shares — an estimated $256K sold.

EntryPoint Capital first reported a position in AGIO in Q4 2023 and held it in 3 quarters. The position peaked at $256K in Q4 2024. 221 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • EntryPoint Capital reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 7,804 Agios Pharmaceuticals shares in Q1 2025, an estimated $256K.
  • EntryPoint Capital first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Agios Pharmaceuticals position peaked at $256K in Q4 2024.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.